|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Wolfgang M. Baiker, Corporate Head of Development, Boehringer Ingelheim
|
|
|
|
James Bailey, GSK Team Leader, Medicinal Chemsitry, GSK
|
|
|
|
Sophie Banzet, Head of Safety Science CNS, Roche
|
|
|
|
Gabriel Bavarel, CEO Metabolys
|
|
|
|
Carles Callol Massot, Scientific Director Biobide S.L.
|
|
|
|
Mireille Cantarini, Internal Clinical genetics Expert, Astrazeneca
|
|
|
|
Annick Cauvin, Senior Principal Scientist, Toxicology, UCB
|
|
|
|
Gvido Cebers, Principal Scientist, CNSP Research Area Toxicologist, Global Safety Assessment, Astrazeneca
|
|
|
|
Dominique, Demolle, CEO, Aepodia
|
|
|
|
Martin Elmlinger, Director Biomarkers, Nycomed
|
|
|
|
Angela, Flannery Director, R&D Science Policy, Astrazeneca
|
|
|
|
Catharine Goddard, Translational Scientist, Pfizer, TMRC lab
|
|
|
|
Chris Goldring, Senior lecturer, MRC Centre for Drug Safety Science, Department of Pharmacology & Therapeutics
|
|
|
|
Guidp Hannauer, Director, Head of General and Safety Pharmacology, Nycomed GmbH
|
|
|
|
Dr. Thomas Herget, Senior Director R&D New Technology Evaluation Performance & Life Science Chemicals, Merck
|
|
|
|
Vicki Ikin, Clinical Biomarker Scientist Group Manager, Astrazeneca
|
|
|
|
Michael, L. Lim, PharmD, Oncology Medicine Development Centre,
|
|
|
|
Roy Mansfield, Director Safety and Risk Management, Pfizer
|
|
|
|
Dr. Julian C. Matthews, Senior Lecturer in the School of Cancer and Imaging Sciences, University of Manchester
|
|
|
|
Helen Mckeever, Pre-clinical Programme Manager Almac
|
|
|
|
Howard Mellor, Pre-Clinical Safety Scientist, General Toxicology Sciences, Safety Assessment UK, Astrazeneca
|
|
|
|
David Nicholson, Senior Vice President and Head, Worldwide Licensing and Knowledge Management, Merck & Co., Inc
|
|
|
|
Michael O'Connell, Director, Life Sciences, Clinical Practice, Spotfire, TIBCO Software INC.
|
|
|
|
Elke Persohn, Head of Cellular Imaging Group, Novartis
|
|
|
|
Marc Princivalle, Director of Toxicology, Research and Preclinical Development & Head of Preclinical Rish Assessment, EMEA, Stiefel (GSK)
|
|
|
|
Eugenii Rabiner, Director, Clinical Imaging Applications, GSK
|
|
|
|
Mandana Rezwan, Head R&D, Dualsystems Biotech
|
|
|
|
Tino Rossi, VP Preclinical Drug Discovery & Enabling Technologies, Neurosciences CEDD, GlaxoSmithKline
|
|
|
|
Thomas Steinbach, Senior Director Safety Surveillance & Risk Management, Wyeth
|
|
|
|
Linda Surh, Director, Global Regulatory Affairs (GRA) Discovery, GSK
|
|
|
|
Austin Tanney, Scientific Liaison Manager, Almac
|
|
|
|
Jean-Pierre Valentin, Director Safety Pharmacology AstraZeneca
|
|
|
|
Philippe Van der Auwera, Global Head of Safety, Roche
|
|
|
|
Will Watson, Senior Partnering Director, Teva Innovative ventures
|
|
|
|
Derek Zhang, Vice President of Clinical Pharmacology and Regulatory Affairs, Frontage laboratories
|
|
|
|
|
|
|
|
Speakers
